An estimated 1 in 500 people in the U.S. are living with hypertrophic cardiomyopathy (HCM) -; the most common inherited heart disease -; and many are unaware.
Hosted on MSN5h
Is Bristol-Myers Squibb Stock Outperforming the Nasdaq?Bristol-Myers Squibb Company (BMY), headquartered in New York and with a market cap of $121.6 billion, is a global leader in ...
Research in idiopathic pulmonary fibrosis is progressing rapidly, with the goal of delivering more treatments to patients at ...
Low- and middle-income countries (LMICs) are undergoing a significant health transformation. While once predominantly ...
LONDON (Reuters) - Some of the world's largest hedge funds are hiring doctors, scientists and analysts to give them expert ...
Bristol Myers Squibb Co. closed $2.39 below its 52-week high ($61.08), which the company reached on November 11th.
Artificial intelligence (AI) is changing the way companies do business -- helping programmers write code and fielding ...
Keros’ elritercept has shown promising efficacy signals in myelofibrosis and myelodysplastic syndromes and could pose a ...
RWJBarnabas Health appoints Steven Stylianos, MD as system director for pediatric surgery and surgeon-in-chief at Bristol-Myers Squibb Children's Hospital ...
BMS has been among the pharma giants that have bought into AI for drug discovery. In 2021, the company struck a $1.2 billion ...
Progression-free survival was improved among patients who received nivolumab and ipilimumab, and toxicity was generally greater among patients who received chemotherapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback